Eli Lilly takes aim at illicit market for its experimental weight-loss drug

Eli Lilly has filed lawsuits against six firms accused of selling counterfeit versions of its experimental obesity drug retatrutide, marking a direct legal assault on a growing black market for the weight‑loss injection. The filings were announced in a press release that also called on online platforms, payment processors and regulators to intervene. The lawsuits follow reports that unauthorized sellers have begun offering retatrutide knockoffs online, exploiting patient demand for new weight‑loss treatments.

Eli Lilly's legal action is framed as a defensive step to protect patients and preserve the scientific validity of its experimental program. Most outlets repeat the company's press release, offering little detail on the identities of the six defendants or the specific platforms implicated. qz.com and the Wall Street Journal note the lawsuits but do not name the alleged online marketplaces, while CBS News highlights the broader issue of counterfeit weight‑loss drugs without quantifying the market size. The coverage does not clarify how payment companies are being targeted or what regulatory mechanisms are being invoked.

The pending litigation leaves open how courts will address the alleged violations and whether regulators will issue direct enforcement actions. No statements have been released about the scale of counterfeit retatrutide distribution, nor about any upcoming policy proposals to curb similar pharmaceutical black markets. Future updates from the Justice Department or the Food and Drug Administration could shape the next phase of the dispute.